A real world study assessing the efficacy of first-line combination therapies for metastatic renal cell carcinoma
Latest Information Update: 01 Apr 2022
At a glance
- Drugs Avelumab (Primary) ; Axitinib (Primary) ; Cabozantinib (Primary) ; Lenvatinib (Primary) ; Nivolumab (Primary) ; Pazopanib (Primary) ; Pembrolizumab (Primary) ; Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
Most Recent Events
- 01 Apr 2022 New trial record
- 19 Feb 2022 Results presented at the 2022 Genitourinary Cancers Symposium